1.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: RTOG 1216, NCI-2013-00500, U10CA021661, NCT01810913
|
|
2.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000651536, RTOG-0920, NCT00956007
|
|
3.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000675520, NCCTG-N09C6, N09C6, NCT01156142
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1200.131, 2011-000392-14, NCT01345669
|
|
5.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000727295, NCCTG-N11C5, N11C5, NCT01545687
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: X90003, NCT00660218
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CDR0000634258, SCCC-112008-019, ABX 236-HN08US, 112008-019, NCT00851877
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: J08101, CA180123, NCT00882583
|
|
9.
|
Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 603EUSA03, NCT00901732
|
|
10.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 06-121, 1R21CA130241-01A1, NCT00903461
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 85 Sponsor: Other Protocol IDs: CLIN-003-09S, NCT00953849
|
|
12.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GCO # 06-0509, NCT00970502
|
|
13.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PX-866-002, NCT01204099
|
|
14.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 2009-0517, NCT01219673
|
|
15.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: WCI1761-09, NCT01283334
|
|
16.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7050-702, 2011-000773-31, NCT01332266
|
|
17.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1266, NA_00074085, NCT01732640
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BrUOG 254, NCT01744340
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 07-0142 / 201106342, NCT00593840
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: UPCI 07-021, NCT00703976
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000600998, P30CA012197, CCCWFU-60108, CCCWFU-IRB- IRB00005784, SANOFI-AVENTIS-CCCWFU-60108, NCT00721513
|
|
22.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 06-120, NCT00798655
|
|
23.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2008-0342, NCT00957853
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 09-083, NCT00968435
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090214, 09-C-0214, NCT00978250
|